title: Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
abstract: Salivary duct carcinoma (SDC) shares significant morphologic and immunophenotypic overlap with ductal carcinoma of the breast, including HER-2/neu expression. Previous studies have detected HER-2/neu at the protein level in SDCs; however, no study, to date, has assayed whether this expression is related to gene amplification detected by chromogenic in situ hybridization (CISH). Formalin-fixed, paraffin-embedded tissue sections from 12 previously diagnosed SDCs were evaluated by immunohistochemistry (IHC) and CISH for HER-2/neu status. Result concordance was seen in all 12 cases. A total of 4 SDCs were positive by IHC; all 4 cases showed amplification with CISH. The remaining 8 cases were negative by IHC and showed no gene amplification with CISH. SDCs in this study show HER-2/neu overexpression on both the protein and gene levels in approximately 30% of cases. These findings suggest a role may exist for Herceptin (trastuzumab) based therapy in some SDC patients.
authors: Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
authors: Christopher J
authors: CJ
authors: Johnson
authors: Michelle B
authors: MB
authors: Barry
authors: Mohammad A
authors: MA
authors: Vasef
authors: Barry R
authors: BR
authors: Deyoung
mesh_terms: D044584:Carcinoma, Ductal / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization / Q000379:methods; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D012468:Salivary Gland Neoplasms / Q000378:metabolism*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases